HomeCompareBRSI vs JNJ

BRSI vs JNJ: Dividend Comparison 2026

BRSI yields 2000000.00% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BRSI wins by $1.6247481716182984e+23M in total portfolio value
10 years
BRSI
BRSI
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6247481716182984e+23M
Annual income
$147,608,011,402,949,780,000,000,000,000.00
Full BRSI calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — BRSI vs JNJ

📍 BRSI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRSIJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRSI + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BRSI pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRSI
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$125,466,809,692,507,310,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, BRSI beats the other by $125,466,809,692,507,310,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRSI + JNJ for your $10,000?

BRSI: 50%JNJ: 50%
100% JNJ50/50100% BRSI
Portfolio after 10yr
$8.123740858091492e+22M
Annual income
$73,804,005,701,474,890,000,000,000,000.00/yr
Blended yield
90.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BRSI
No analyst data
Altman Z
-0.3
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRSI buys
0
JNJ buys
0
No recent congressional trades found for BRSI or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRSIJNJ
Forward yield2000000.00%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$1.6247481716182984e+23M$30.5K
Annual income after 10y$147,608,011,402,949,780,000,000,000,000.00$4,749.88
Total dividends collected$1.6146053563276882e+23M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BRSI vs JNJ ($10,000, DRIP)

YearBRSI PortfolioBRSI Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$100,010,700$100,000,000.00$10,594$274.49+$100.00MBRSI
2$467,446,731,075$467,339,719,626.17$11,294$360.69+$467446.72MBRSI
3$1,021,215,363,816,662$1,020,715,195,814,411.90$12,133$476.91+$1021215363.80MBRSI
4$1,043,112,617,104,109,200$1,042,019,916,664,825,300.00$13,156$635.42+$1043112617104.10MBRSI
5$498,482,143,759,731,400,000$497,366,013,259,430,040,000.00$14,432$854.61+$498482143759731.38MBRSI
6$111,599,275,650,097,780,000,000$111,065,899,756,274,860,000,000.00$16,056$1,162.76+$111599275650097776.00MBRSI
7$11,738,678,336,351,557,000,000,000$11,619,267,111,405,953,000,000,000.00$18,175$1,604.53+$11738678336351557632.00MBRSI
8$583,674,362,697,175,100,000,000,000$571,113,976,877,278,900,000,000,000.00$21,009$2,252.68+$583674362697175072768.00MBRSI
9$13,894,210,989,607,547,000,000,000,000$13,269,679,421,521,570,000,000,000,000.00$24,911$3,229.73+$1.3894210989607547e+22MBRSI
10$162,474,817,161,829,840,000,000,000,000$147,608,011,402,949,780,000,000,000,000.00$30,458$4,749.88+$1.6247481716182984e+23MBRSI

BRSI vs JNJ: Complete Analysis 2026

BRSIStock

Ballistic Recovery Systems Inc. develops and commercializes parachute systems in the United States. The company operates in three segments: Aviation, Defense, and Space. The Aviation segment designs, tests, and produces whole-aircraft emergency recovery parachute systems for the general aviation and recreational aircraft industries. The Defense segment designs, tests, and produces personnel parachute systems, precision guided aerial delivery systems, and cargo and whole-aircraft emergency recovery parachutes used in unmanned aerial vehicles and training aircrafts. The Space segment designs, tests, and produces entry, descent, and landing systems for various space applications, as well as manned and un-manned, planetary, and terrestrial space applications. The company also provides safety apparel. Ballistic Recovery Systems Inc. was founded in 1980 and is based in South Saint Paul, Minnesota.

Full BRSI Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this BRSI vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRSI vs SCHDBRSI vs JEPIBRSI vs OBRSI vs KOBRSI vs MAINBRSI vs ABBVBRSI vs MRKBRSI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.